Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. Ismaila AS, et al. Among authors: compton c. Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1. Adv Ther. 2023. PMID: 37004642 Free PMC article. No abstract available.
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Pascoe S, et al. Among authors: compton c. Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4. Lancet Respir Med. 2019. PMID: 31281061 Clinical Trial.
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF. Maltais F, et al. Among authors: compton c. Respir Res. 2019 Oct 30;20(1):238. doi: 10.1186/s12931-019-1193-9. Respir Res. 2019. PMID: 31666084 Free PMC article. Clinical Trial.
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F. Vogelmeier CF, et al. Among authors: compton c. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620968500. doi: 10.1177/1753466620968500. Ther Adv Respir Dis. 2020. PMID: 33167780 Free PMC article. Clinical Trial.
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD.
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG. Bourbeau J, et al. Among authors: compton c. Int J Chron Obstruct Pulmon Dis. 2021 Mar 1;16:499-517. doi: 10.2147/COPD.S291967. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33688176 Free PMC article. Review.
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement.
Vogelmeier CF, Naya IP, Maltais F, Bjermer L, Kerwin EM, Tombs L, Jones PW, Compton C, Lipson DA, Boucot IH. Vogelmeier CF, et al. Among authors: compton c. Int J Chron Obstruct Pulmon Dis. 2021 May 3;16:1215-1226. doi: 10.2147/COPD.S295835. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33976543 Free PMC article. Clinical Trial.
510 results